Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Enzastaurin [170364-57-5]

Enzastaurin [170364-57-5]

Imprimer Imprimer
Identifiez-vous

Référence HY-10342-10mg

Conditionnement : 10mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Enzastaurin (LY317615) is a potent, selective, and CNS-penetrant PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε[1][2][3][4].

IC50 & Target[3]

PKCβ

6 nM (IC50)

PKCα

39 nM (IC50)

PKCγ

83 nM (IC50)

PKCε

110 nM (IC50)

Cellular Effect
Cell Line Type Value Description References
PANC-1 IC50
6.59 μM
Compound: Enzastaurin
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
[PMID: 39151060]
In Vitro

Enzastaurin (LY317615) application results in a marked dose-dependent inhibition of growth in all MM cell lines investigated, including MM.1S, MM.1R, RPMI 8226 (RPMI), RPMI-Dox40 (Dox40), NCI-H929, KMS-11, OPM-2, and U266, with IC50 from 0.6-1.6 μM. Enzastaurin direct impacts human tumor cells, inducing apoptosis and suppressing proliferation in cultured tumor cells. Enzastaurin also suppresses the phosphorylation of GSK3βser9, ribosomal protein S6S240/244, and AKTThr308 while having no direct effect on VEGFR phosphorylation[1].
Enzastaurin increases apoptosis in malignant lymphocytes of CTCL. When combined with GSK3 inhibitors, enzastaurin demonstrates an enhancement of cytotoxicity levels. Treatment with a combination of enzastaurin and the GSK3 inhibitor AR-A014418 leads to increased levels of β-catenin total protein and β-catenin-mediated transcription. Blocking of β-catenin-mediated transcription or small hairpin RNA (shRNA) knockdown of β-catenin induces the same cytotoxic effects as that of enzastaurin plus AR-A014418. Additionally, treatment with enzastaurin and AR-A014418 decreases the mRNA levels and surface expression of CD44[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Enzastaurin Related Antibodies
In Vivo

Treatment of xenografts with Enzastaurin and radiation produces greater reductions in density of microvessels than either treatment alone. The decrease in microvessel density corresponds to delayed tumor growth[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Masse moléculaire

515.61

Formule

C32H29N5O2
CAS No.
Appearance

Solid

Color

Orange to red

SMILES

O=C(C(C1=CN(C)C2=C1C=CC=C2)=C3C4=CN(C5CCN(CC6=NC=CC=C6)CC5)C7=C4C=CC=C7)NC3=O
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
Solvant et solubilité
In Vitro: 

DMSO : 8.33 mg/mL (16.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9395 mL 9.6973 mL 19.3945 mL
5 mM 0.3879 mL 1.9395 mL 3.8789 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 0.83 mg/mL (1.61 mM); Clear solution

    This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 0.83 mg/mL (1.61 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 0.83 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT
HY-10249-10mg
GSK-690693 [937174-76-0]
 10mg 
HY-12067-10mg
R406 [841290-81-1]
 10mg 
HY-13254-10mg
A-674563 [552325-73-2]
 10mg